

## DANA P. GOLDMAN

### BUSINESS ADDRESS

University of Southern California  
635 Downey Way  
Verna & Peter Dauterive Hall  
Los Angeles, CA 90089-3333

### SOCIAL MEDIA

e-mail: [dana.goldman@usc.edu](mailto:dana.goldman@usc.edu)  
Web: <https://healthpolicy.usc.edu/author/dana-goldman-ph-d/>  
LinkedIn: [www.linkedin.com/in/dana-goldman-9a07467](http://www.linkedin.com/in/dana-goldman-9a07467)

### EDUCATION

- 1994 Ph.D., Economics  
**Stanford University**  
450 Serra Mall  
Stanford, CA 94305
- 1988 B.A., Economics, *Summa Cum Laude*  
**Cornell University**  
300 Day Hall  
Ithaca, NY 14853
- 1984 High school Diploma  
**Lexington High School**  
251 Waltham St  
Lexington, MA 02421

### APPOINTMENTS

- 2020-Present Interim Dean, USC Sol Price School of Public Policy
- 2013-Present Leonard D. Schaeffer Director's Chair  
Distinguished Professor of Public Policy, Pharmacy, and Economics,  
**University of Southern California**
- 2017-Present Nonresident Senior Fellow, Economic Studies Program, **Brookings Institution**
- 2002-Present Research Associate, **National Bureau of Economic Research**
- 2009-Present Director, **Leonard D. Schaeffer Center for Health Policy & Economics**
- 2009-2013 Norman Topping Chair in Medicine and Public Policy, **University of Southern California**
- 2005-2011 Adjunct Professor, **UCLA**, Health Policy and Management
- 2005-2011 Adjunct Professor, **UCLA**, Radiology
- 2006-2009 Director, Health Economics, Finance, and Organization, **RAND**
- 1999-2009 Professor of Economics, **Pardee RAND Graduate School**
- 2003-2009 Distinguished Chair in Health Economics, **RAND**, 1776 Main St, Santa Monica, CA 90401
- 2000-2005 Adjunct Associate Professor, **UCLA** Health Services and Radiology
- 1998-2002 Senior Economist, **RAND**, 1776 Main St, Santa Monica, CA 90401
- 1996-2000 Adjunct Assistant Professor, **UCLA**, Health Services
- 1996-1998 Economist, **RAND**, 1776 Main St, Santa Monica, CA 90401
- 1994-1996 Visiting Assistant Professor, **UCLA**, Economics
- 1993-1996 Associate Economist, **RAND**, 1776 Main St, Santa Monica, CA 90401

## HONORS AND AWARDS

2018	Founding Institute Member, Lawrence J. Ellison Institute for Transformative Medicine
2018	Member, National Academy of Social Insurance
2018	Inaugural Associate Member, Center for the Economics of Human Development
2017	Associates Award for Creativity in Research*, University of Southern California
2016	Distinguished Professor, University of Southern California
2015	Robert Biller Outstanding Faculty Award, Price School of Public Policy
2012	USC Mellon Mentoring Award
2011	MetLife Foundation Silver Scholar Award
2009	Member, National Academy of Medicine
2009	Eugene Garfield Economic Impact of Medical and Health Research Award
2006	Edwin E. Huddleson, Jr. Outstanding Teacher Award, RAND Graduate School
2002	Annual Research Award, National Institute for Health Care Management
2002	Alice S. Hersh New Investigator Award, AcademyHealth
2000	Article of the Year, Association for Health Services Research
1993	Stanford University Fellowship in Health Care Research and Health Policy
1992	John M. Olin Fellowship for Research in Economic Policy
1988	<i>Summa Cum Laude</i> with Distinction in All Subjects, Cornell University
1988	Phi Beta Kappa, Cornell University
1984	National Merit Scholar

## PROFESSIONAL ACTIVITIES

### Training & Research:

2004-Present	Director, NIA Roybal Center for Health Policy Simulation
1996-2013	Director, UCLA/RAND Health Services Research Postdoctoral Training Program
2006-2009	Director, Bing Center for Health Economics, RAND
1997-2007	Director, RAND Summer Institute

### Teaching:

2012-Present	Health Economics, USC
2010-Present	Graduate Seminar in Pharmaceutical Economics and Policy, USC
2009-Present	Introduction to Health Policy and Management, USC
1997-2007	Health Economics, Pardee RAND Graduate School
1994-1995	Government Regulation of Labor Markets, UCLA Department of Economics
1994	Introduction to Labor Economics, UCLA Department of Economics
1991	Intermediate Econometrics, Stanford University (teaching assistant)

### Editorial Boards:

2012-Present	<i>Evidence-Based Diabetes</i>
2012-Present	<i>Evidence-Based Oncology</i>
2005-Present	<i>Forum for Health Economics and Health Policy</i> (founding co-editor)
2003-Present	<i>Health Affairs</i>
2003-Present	<i>American Journal of Managed Care</i>
2002-Present	<i>B.E. Journals in Economic Analysis and Policy</i>
1996-1998	<i>RAND Journal of Economics</i>

---

\* Associates awards are "the highest honors the university faculty can bestow on its members for distinguished intellectual and artistic achievements."

**Advisory Panels:**

2020-2020	GRAIL Scientific Advisory Board
2013-2020	Fred Hutchinson Cancer Institute, HICOR Advisory Board (Chair)
2017-2020	ACADIA Pharmaceuticals Scientific Advisory Board
2014-2017	Board of Directors, International Society for Pharmacoeconomics and Outcomes Research
2013-2014	World Economic Forum's Global Agenda Council on Personalized and Precision Health
2012-2013	PhRMA Adherence Advisory Council
2011-2013	World Economic Forum's Global Agenda Council on Genetics
2009-2010	National Academy of Science Panel to Improve Medicare Cost Projections (Chair)
2008-2012	Board of Directors, American Society of Health Economists
2008-2017	Congressional Budget Office, Panel of Health Advisers
2008-2010	National Academy of Science Panel on Fiscal Future of the United States
2006-2008	Institute of Medicine Committee on the Value of Clinical Services
2005-2009	International Health Economics Association, Scientific Advisory Committee
2007-2016	MacArthur Foundation, Research Network on an Aging Society
2007-2008	National Institutes of Health, Special Emphasis Panel
2005-2006	AcademyHealth, Planning Committee for Annual Research Meeting
2005-2006	National Academy of Sciences, Expert Panel on the Future of the NLTCs
2003-2007	National Institute on Aging, Behavior and Social Science of Aging study section
2002-2005	Berkeley Electronic Press, Board of Directors
2002-2004	Institute of Medicine, Behavioral and Social Sciences in Medical School Curricula
1997-1998	Agency for Health Care Policy and Research, Special Emphasis Panel

**Expert Testimony:**

2005	California Assembly Health Committee, Sacramento, CA
1993	Senate Labor and Human Resources Committee, Washington D.C.
1992	House Ways and Means Subcommittee on Health, Washington D.C.

**Selected Media:**

<b>Television</b>	<i>ABC News (Nightline), CNN World News, CNN Headline News, NBC News with Tom Brokaw, CBS Nightly News with Dan Rather, CBS Evening News with Katie Couric</i>
<b>Radio</b>	NPR All Things Considered, KNX, KQED
<b>Newspaper</b>	<i>Wall Street Journal, Los Angeles Times, New York Times, Washington Post, Miami Herald, Boston Globe, Boston Herald, San Francisco Chronicle</i>
<b>Magazine</b>	<i>Business Week, U.S. News &amp; World Report, Time</i>

**Professional Organizations:**

AEA, PAA, IHEA, ASHEcon, AcademyHealth, ISPOR

**PUBLICATIONS**

**Journals**

1. Agtarap S, et al, **TRACK-TBI Investigators**. "Invariance of the Bifactor Structure of Mild Traumatic Brain Injury (mTBI) Symptoms on the Rivermead Postconcussion Symptoms Questionnaire Across Time, Demographic Characteristics, and Clinical Groups: A TRACK-TBI Study." *Assessment*, 1073191120913941, 2020.
2. Kabiri M, Sexton Ward A, Ramasamy A, van Eijndhoven E, Ganguly R, Smolarz B, Zvenyach T, **Goldman D**, et al. "The Societal Value of Broader Access to Antiobesity Medications."

- Obesity*, 28(2):429-436, 2020.
3. Myerson R, Tucker-Seeley R, **Goldman D**, Lakdawalla D. "Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?"  
*Journal of Policy Analysis and Management*, 2020.
  4. Li M, Lakdawalla D, **Goldman D**. "Association Between Spending and Outcomes for Patients With Cancer."  
*Journal of Clinical Oncology*, 38(4):323-331, 2020.
  5. Mulligan K, Seabury S, Dugel P, Blim J, **Goldman D**, Humayun M. "Economic Value of Anti-Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States."  
*JAMA Ophthalmology*, 138(1):40-47, 2020.
  6. Mattke S, Schneider S, Orr P, Lakdawalla D, **Goldman D**. "Temporal Trends in Mortality After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Regression Analysis."  
*Structural Heart*, 4(1):16-23, 2020.
  7. Trish E, Ginsburg P, Joyce G, **Goldman D**. "Who Pays in Medicare Part D? Giving Plans More Skin in the Game."  
*New England Journal of Medicine*, 381(25):2384-2387, 2019.
  8. Sharp S, Gascue L, **Goldman D**, et al. "Higher Surgeon Procedure Volume is Associated with Improved Hemodialysis Vascular Access Outcomes."  
*The American Surgeon*, 85(10):1079-1082, 2019.
  9. Chiou T, Tsugawa Y, **Goldman D**, et al. "Trends in Racial and Ethnic Disparities in Diabetes-Related Complications, 1997–2017."  
*Journal of General Internal Medicine*, 2019.
  10. MacEwan JP, Doctor J, Mulligan K, May SG, Batt K, Zacker C, Lakdawalla D, **Goldman D**. "The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers."  
*MDM Policy & Practice*, 21;4(1):2381468319855386, 2019.
  11. Dikmen S, et al, **Track-TBI Investigators**. "Functional Status Examination Versus Glasgow Outcome Scale Extended as Outcome Measures in Traumatic Brain Injuries: How Do They Compare?"  
*Journal of Neurotrauma*, 15;36(16):2423-2429, 2019.
  12. Snider J, Duncan M, Gore M, Seabury S, Silverstein A, Tebeka M, **Goldman D**. "Association Between State Medicaid Eligibility Thresholds and Deaths Due to Substance Use Disorders."  
*JAMA Network Open*, 2(4):e193056, 2019.
  13. Xie Z, St. Clair P, **Goldman D**, Joyce G. "Racial and ethnic disparities in medication adherence among privately insured patients in the United States."  
*PLoS ONE*, 14(2):e0212117, 2019.
  14. Seabury S, Axeen S, Pauley G, Tysinger B, Schlosser D, Hernandez J, Heun-Johnson H, Zhao H, **Goldman D**. "Measuring the Lifetime Costs of Serious Mental Illness and the Mitigating Effects of Educational Attainment."  
*Health Affairs*, 38(4):652-659, 2019.
  15. Chen C, **Goldman D**, et al. "The Long-Term Impact of Functional Disability on Hospitalization Spending in Singapore."  
*The Journal of the Economics of Ageing*, 14:100193, 2019.
  16. Chou J, Silverstein A, **Goldman D**. "Short-term Budget Affordability of Hepatitis C Treatments for State Medicaid Programs."  
*BMC Health Services Research*, 19(1):1-13, 2019.
  17. Stein M, et al, **TRACK-TBI Investigators**. "Risk of Posttraumatic Stress Disorder and Major Depression in Civilian Patients After Mild Traumatic Brain Injury."

- JAMA Psychiatry*, 76(3):249–258, 2019.
18. **Goldman D**, et al. "A New Model for Pricing Drugs of Uncertain Efficacy." *NEJM Catalyst*, Published online December 13, 2018.
  19. Shekelle P, **Goldman D**. "Development of a Group Judgment Process for Forecasts of Health Care Innovations." *JAMA Network Open*, 1(7):e185108, 2018.
  20. Huie J, et al, **Track-TBI Investigators**. "Testing a Multivariate Proteomic Panel for Traumatic Brain Injury Biomarker Discovery: A Track-TBI Pilot Study." *Journal of Neurotrauma*, 36(1):100-110, 2018.
  21. Chen A, **Goldman D**. "Productivity Benefits of Medical Care: Evidence from US-Based Randomized Clinical Trials." *Value in Health*, 21(8):905-910, 2018.
  22. Chen C, **Goldman D**, Zissimopoulos J, Rowe JW. "Multidimensional comparison of countries' adaptation to societal aging." *Proceedings of the National Academy of Sciences*, 115(37): 9169-9174, 2018.
  23. Seabury S, Gaudette E, **Goldman D**, et al, TRACK-TBI Investigators. "Assessment of Follow-up Care After Emergency Department Presentation for Mild Traumatic Brain Injury and Concussion Results From the TRACK-TBI Study." *JAMA Network Open*, 1(1):e180210, 2018.
  24. **Goldman D**, Fillit H, Neumann P. "Accelerating Alzheimer's disease drug innovations from the research pipeline to patients." *Alzheimer's & Dementia*, 14(6):833-836, 2018.
  25. Cefalu WT, Dawes DE, Gavlak G, **Goldman D**, et al. "Insulin Access and Affordability Working Group: Conclusions and Recommendations." *Diabetes Care*, 41(6):1299-1311, 2018.
  26. Kabiri M, Brauer M, Shafrin J, Sullivan J, Gill T, **Goldman D**. "The Long-Term Health and Economic Value of Improved Mobility among Older Adults in the United States." *Value in Health*, 21(7):792-798, 2018.
  27. Van Nuys K, Xie Z, Tysinger B, Hlatky M, **Goldman D**. "Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities." *JACC: Heart Failure*, 6(5):401-409, 2018.
  28. Van Nuys K, Joyce G, Ribero R, **Goldman D**. "Frequency and Magnitude of Co-payments Exceeding Prescription Drug Costs." *JAMA*, 319(10):1045-1047, 2018.
  29. Turakhia MP, Shafrin J, Bogner K, Trocio J, Abdulsattar Y, Wiederkehr D, **Goldman D**. "Estimated Prevalence of Undiagnosed Atrial Fibrillation in the United States." *PLoS One*, 13(4):e0195088, 2018.
  30. Jena A, Olenski A, Blumenthal D, Yeh R, **Goldman D**, Romley J. "Acute Myocardial Infarction Mortality During Dates of National Interventional Cardiology Meetings." *Journal of the American Heart Association*, 7(6), 2018.
  31. **Goldman D**, Chen C, Zissimopoulos J, Rowe J. "Opinion: Measuring how nations adapt to societal aging." *Proceedings of the National Academy of Sciences*, 115(3):435-437, 2018.
  32. Carrera M, **Goldman D**, Joyce G, Sood N. "Do Physicians Respond to the Costs and Cost-Sensitivity of Their Patients?"

- American Economic Journal: Economic Policy*, 10(1), 2018.
33. Sachs R, Ginsburg P, **Goldman D**. "Encouraging New Uses for Old Drugs." *JAMA*, 318(24):2421-2422, 2017.
  34. Palacios E, et al, **Track-TBI Investigators**. "Toward Precision and Reproducibility of Diffusion Tensor Imaging: A Multicenter Diffusion Phantom and Traveling Volunteer Study." *American Journal of Neuroradiology*, 38(3):537-545, 2017.
  35. **Goldman D** and Hagopian, K. "Medicare-for-All: Not Our Only Option for Universal Coverage." *Journal of Policy Analysis and Management*, 37:195–198, 2017.
  36. **Goldman D** and Hagopian, K. "It is Time for Universal Coverage Without Breaking the Bank." *Journal of Policy Analysis and Management*, 37:182–188, 2017.
  37. Gonzalez-Gonzalez C, Tysinger B, **Goldman D**, et al. "Projecting diabetes prevalence among Mexicans aged 50 years and older: The Future Elderly Model-Mexico (FEM-Mexico)." *BMJ Open*, 7:e017330, 2017.
  38. Blumenthal D, **Goldman D**, Jena A. "Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK 9 Inhibitors." *JAMA Cardiology*, 2(10):1063-1064, 2017.
  39. Shafrin J, Sullivan J, **Goldman D**, Gill T. "The association between observed mobility and quality of life in the near elderly." *PLoS One*, 12(8):e0182920, 2017.
  40. St. Clair P, **Goldman D**, et al. "Using Self-reports or Claims to Assess Disease Prevalence." *Medical Care*, 55(8):782-788, 2017.
  41. Auerbach A, **Goldman D**, et al. "How the Growing Gap in Life Expectancy May Affect Retirement Benefits and Reforms." *The Geneva Papers on Risk and Insurance*, 42(3):475-499, 2017.
  42. Van Nuys K, Chou J, Silverstein A, Brookmeyer R, **Goldman D**. "The impact of broader hepatitis C treatment strategies on population health and social value in England." *Journal of Hepatology*, 66(1):S407-S407, 2017.
  43. Zissimopoulos J, Blaylock B, **Goldman D**, Rowe J. "Raising the Social Security Entitlement Age: Implications for the Productive Activities of Older Adults." *Research on Aging*, 39(1):166–189, 2017.
  44. Cheng W, Gaudette E, **Goldman D**. "PCSK9 Inhibitors Show Value for Patients and the US Health Care System." *Value in Health*, 20(10):1270-1278, 2017.
  45. Blumenthal D, **Goldman D**, Jena A. "Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals." *Annals of Internal Medicine*, 166(3):219-220, 2017.
  46. Woo K, Gascue L, **Goldman D**, Romley J. "Variations in outcomes of hemodialysis vascular access by race/ethnicity in the elderly." *Journal of Vascular Surgery*, 65(3):783-792, 2017.
  47. Jena A, **Goldman D**, Karaca-Mandic P. "Hospital Prescribing of Opioids to Medicare Beneficiaries." *JAMA Internal Medicine*, 176(7):990-997, 2016.
  48. Agus D, Gaudette É, **Goldman D**, Messali A. "The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older." *PLoS One*, 11(11):e0166103, 2016.

49. Snider J, Seabury S, Lopez J, McKenzie S, Wu Y, **Goldman D**. "Impact of Type 2 Diabetes Medication Cost-sharing on Patient Outcomes and Health Plan Costs."  
*American Journal of Managed Care* 22(6):433-440, 2016.
50. Jena A, Blumenthal D, Stevens W, Chou J, Ton T, **Goldman D**. "Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events."  
*American Journal of Managed Care*, 22(6):e199-207, 2016.
51. **Goldman D**, Gaudette E, Cheng W. "Competing Risks: Investing in Sickness Rather Than Health."  
*American Journal of Preventive Medicine*, 50(5):S45-50, 2016.
52. **Goldman D**. "The Economic Promise of Delayed Aging."  
*Cold Spring Harbor Perspectives in Medicine*, 6(2):a025072, December 18, 2015.
53. Romley JA, Gong C, Jena AB, **Goldman D**, Williams B, Peters A. "Authors' Reply to Bosco-Levy and Salvo."  
*BMJ*, 354: i4330, 2016.
54. Gaudette E, Tysinger B, Cassil A, **Goldman D**. "Health and Health Care of Medicare Beneficiaries in 2030."  
*Forum for Health Economics and Policy*, 18(2):75-96, 2015.
55. Romley J, Gong C, Jena A, **Goldman D**, Williams B, Peters A. "Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis."  
*BMJ*, 351:h6334, 2015.
56. Snider J, **Goldman D**, Rosenblatt L, Seekins D, Juday T, Sanchez Y, Wu Y, Peneva D, Romley J. "The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV."  
*Medical Care Research and Review*, 73(3):329-348, 2015.
57. Nikolich-Žugich J, **Goldman D**, Cohen P, Cortese D, Fontana L, Kennedy B, Mohler M, Olshansky S, Perls T, Perry D, Richardson A, Ritchie C, Wertheimer A, Faragher R, Fain M. "Preparing for an Aging World: Engaging Biogerontologists, Geriatricians, and the Society."  
*Journal of Gerontology Series A*, 71(4):435-44, 2015.
58. Van Nuys K, Brookmeyer R, Chou J, Dreyfus D, Dieterich D, **Goldman D**. "Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern."  
*Health Affairs*, 34(10):1666-74, 2015.
59. Woo K, **Goldman D**, Romley J. "Early Failure of Dialysis Access among the Elderly in the Era of Fistula First."  
*Clinical Journal of the American Society of Nephrology*. 10(10):1791-8, 2015.
60. Lakdawalla D, Chou J, Linthicum M, MacEwan J, Zhang J, **Goldman D**. "Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer."  
*JAMA Oncology*, 1(2):196-202, 2015.
61. Turakhia M, Shafrin J, Bognar K, **Goldman D**, Mendys P, Abdulsattar Y, Wiederkehr D, Trocio J. "Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States."  
*American Journal of Cardiology*, 116(5):733-9, 2015.
62. Dzau V, Ginsburg G, Van Nuys K, **Goldman D**. "Aligning incentives to fulfil the promise of personalized medicine."  
*The Lancet*, 385(9982):2015-2120, May 6, 2015.
63. Gaudette E, **Goldman D**, Messali A, Sood N. "Do Statins Reduce the Health and Health Care Costs of Obesity?"  
*PharmacoEconomics*, 33(7):723-734, 2015.
64. Seabury S, Lakdawalla D, Dougherty S, Sullivan J, **Goldman D**. "Medication Adherence and Measures of Health Plan Quality."  
*American Journal of Managed Care*, 21(6):e379-89, 2015.

65. Romley J, Axeen S, Lakdawalla D, Chernew M, Bhattacharya J, **Goldman D**. "The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization." *Health Services Research*, 50(3):883-96, 2015.
66. Jena A, Ho O, **Goldman D**, Karaca-Mandic, P. "The Impact of the US Food & Drug Administration Chlorofluorocarbon Ban on Out-of-Pocket Costs & Use of Albuterol Inhalers Among Individuals With Asthma." *JAMA Internal Medicine*, 175(7):1171-9, 2015.
67. Eber M, **Goldman D**, Lakdawalla D, Philipson T, Pritchard D, Huesch M, Summers N, Linthicum M, Sullivan J, Dubois R. "Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments." *Journal of Comparative Effectiveness Research*, 4(3):203-213, May 7, 2015.
68. Zissimopoulos J, **Goldman D**, Olshansky S, Rother J, Rowe J. "Individual & Social Strategies to Mitigate the Risks & Expand Opportunities of an Aging America." *Daedalus*, 144 (2):93-102, 2015.
69. Romley J, **Goldman D**, Sood N. "US hospitals experienced substantial productivity growth during 2002-11." *Health Affairs*, 34(3):511-8, 2015.
70. Jena A, **Goldman D**, Seabury S. "Incidence of sexually transmitted infections after human papillomavirus vaccination among adolescent females." *JAMA Internal Medicine*, 175(4):617-23, 2015.
71. Chandra A, Snider J, Wu Y, Jena A, **Goldman D**. "Robot-assisted surgery for kidney cancer increased access to a procedure that can reduce mortality and renal failure." *Health Affairs*, 34(2):220-8, 2015.
72. Jena A, Prasad V, **Goldman D**, Romley J. "Mortality and Treatment Patterns Among Patients Hospitalized With Acute Cardiovascular Conditions During Dates of National Cardiology Meetings." *JAMA Internal Medicine*, 175(2):237-44, 2015.
73. Eber M, **Goldman D**, et al. "Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments." *Journal of Comparative Effectiveness Research*, 4(3):1-11, 2015.
74. Zissimopoulos J, Joyce G, Scarpati L, **Goldman D**. "Did Medicare Part D reduce disparities?" *American Journal of Managed Care*, 21(2):119-28, 2015.
75. Stevens W, Philipson T, Khan Z, MacEwan J, Linthicum M, **Goldman D**. "Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007." *Health Affairs*, 34(4):562-70, 2015.
76. **Goldman D** and Orszag P. "The Growing Gap in Life Expectancy: Using the Future Elderly Model to Estimate Implications for Social Security and Medicare." *American Economic Review: AEA Papers and Proceedings*, 104(5):230-33, 2014.
77. Barcellos S, Wupperman A, Carman K, Bauhoff S, McFadden D, Kapteyn A, Winter J, **Goldman D**. "Preparedness of Americans for the Affordable Care Act." *Proceedings of the National Academy of Sciences*, 111(15):5497-5502, 2014.
78. Romley J, Axeen S, Lakdawalla D, Chernew M, Bhattacharya J, **Goldman D**. "The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization." *Health Services Research*, 50(3):883-96, 2015.
79. Jena A, **Goldman D**, Weaver L, Karaca-Mandic P. "Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims." *BMJ*, 348:g1393, 2014.

80. Trish E, Joyce G, **Goldman D**. "Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11."  
*Health Affairs*, 33(11):2018-24, 2014.
81. **Goldman D**, Philipson T. "Five myths about cancer care in America."  
*Health Affairs*, 33(10):1801-4, 2014.
82. Seabury S, **Goldman D**, Kalsekar I, et al. "Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid."  
*American Journal of Managed Care*, 20(2):e52-60, 2014.
83. Snider J, Juday T, Romley J, Seekins D, Rosenblatt L, Sanchez Y, **Goldman D**. "Nearly 60,000 uninsured and low-income people with HIV/AIDS live in states that are not expanding Medicaid."  
*Health Affairs*, 33(4):724, 2014.
84. Van Nuys K, Gobe D, Ng-Mak D, Cheung H, Sullivan J, **Goldman D**. "The association between employee obesity and employer costs: evidence from a panel of U.S. employers."  
*American Journal of Health Promotion*, 28(5):277-85, 2014.
85. **Goldman D**, Fastenau J, Dirani R, et al. "Medicaid Prior Authorization Policies and Imprisonment Among Patients with Schizophrenia."  
*American Journal of Managed Care*, 20(7):577-586, 2014.
86. Snider J, Bognar K, Glob D, Ng-Mak D, Sullivan J, Summers N, **Goldman D**. "Identifying patients at risk for high medical costs and good candidates for obesity intervention."  
*American Journal of Health Promotion*, 28(4):218-27, 2014.
87. Basu A, Jena A, **Goldman D**, Philipson T, Dubois R. "Heterogeneity in Action: the Role of Passive Personalization in Comparative Effectiveness Research."  
*Health Economics*, 23(3):359-73, 2014.
88. Romley J, Chen A, **Goldman D**, et al. "Hospital Costs and Inpatient Mortality among Children Undergoing Surgery for Congenital Heart Disease."  
*Health Services Research*, 49(2):588-608, 2014.
89. **Goldman D**, Dirani R, Fastenau J, et al. "Do Strict Formularies Replicate Failure for Patients with Schizophrenia?"  
*American Journal of Managed Care*, 20(30):219-228, 2014.
90. **Goldman D**, Juday T, Linthicum M, et al. "The Prospect Of A Generation Free Of HIV May Be Within Reach If The Right Policy Decisions Are Made."  
*Health Affairs*, 33(3):428-33, 2014.
91. Seabury SA, et al, **PhRMA Medication Adherence Advisory Council**. "Understanding and Overcoming Barriers to Medication Adherence: A Review of Research Priorities."  
*Journal of Managed Care Pharmacy*, 20(8): 775-783, 2014.
92. Ryan G, Bloom E, Lowsky DJ, et al. "Data-Driven Decision-Making Tools To Improve Public Resource Allocation For Care And Prevention Of HIV/AIDS."  
*Health Affairs*, 33(3):410-7, 2014.
93. Sood N, Juday T, Vanderpuye-Orgle J, Rosenblatt L, Romley JA, Peneva D, **Goldman D**. "HIV Care Providers Emphasize The Importance Of The Ryan White Program For Access To And Quality Of Care."  
*Health Affairs*, 33(3):394-400, 2014.
94. Romley J, Juday T, Solomon M, Seekins D, Brookmeyer R, **Goldman D**. "Early HIV Treatment Led To Life Expectancy Gains Valued At \$80 Billion For People Infected In 1996-2009."  
*Health Affairs*, 33(3):370-7, 2014.

95. **Goldman D**, Juday T, Seekins D, et al. "Early HIV Treatment in the United States Prevented Nearly 13,500 Infections Per Year During 1996-2009." *Health Affairs*, 33(3):362-9, 2014.
96. Edlin A, **Goldman D**, Leive A. "The Future of US Health Care: Is Medicare Really Better at 'Saving' Money?" *The Economists' Voice*, 11(1):13, 2014.
97. Lowsky J, Olshansky SJ, Bhattacharya J, **Goldman D**. "Heterogeneity in Healthy Aging." *Journal of Gerontology, Series A, Biological Sciences and Medical Sciences*, 69(6):640-649, 2014.
98. **Goldman D**, Olshansky SJ. "Delayed Aging Versus Delayed Disease: A New Paradigm for Public Health." *Public Policy & Aging Report*, 23(4):16-18, 2013.
99. **Goldman D**, McFadden D, Newhouse J. "Introduction. American Medicare Program, Parts C and D." *Journal of Health Economics* 32(6):1258-1262, 2013.
100. Joyce G, Zissimopoulos J, **Goldman D**. "Digesting the Doughnut Hole." *Journal of Health Economics*, 32(6):1345-1355, 2013.
101. **Goldman D**, Cutler D, Rowe J, et al. "Substantial Health and Economic Returns From Delayed Aging May Warrant a New Focus For Medical Research." *Health Affairs*, 32(10):1698-1705, 2013.
102. **Goldman D**, Gupta C, Vasudeva E, et al. "The Value of Diagnostic Testing in Personalized Medicine." *Forum for Health Policy and Economics*, 16(20):121-133, 2013.
103. Lakdawalla D, Eber M, Forma F, Sullivan J, Michaud P, Bradley L, **Goldman D**. "Measuring the Value of Better Diabetes Management." *American Journal of Managed Care*, 10(Special Issue 2):SP70-76, 2013.
104. Eibner C, **Goldman D**, Sullivan J, et al. "Three Large-Scale Changes to the Medicare Program Could Curb its Costs but Also Reduce Enrollment." *Health Affairs*, 32(5):891-899, 2013.
105. Romley J, Jena A, O'Leary J, **Goldman D**. "Spending and Mortality in US Acute Care Hospitals." *American Journal of Managed Care*, 19(2):e46-54, 2013.
106. Philipson T, Snider J, Lakdawalla D, Stryckman B, **Goldman D**. "Impact of Oral Nutritional Supplementation on Hospital Outcomes." *American Journal of Managed Care*, 19(2):121-128, 2013.
107. Chernew M, et al. "Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes." *American Journal of Managed Care*, 19(2):93-96, 2013.
108. Jena AB, Sun E, **Goldman D**. "Confounding in the Association of Proton Pump Inhibitor Use with Risk of Community-Acquired Pneumonia." *Journal of General Internal Medicine*, 28(2):223-230, 2013.
109. **Goldman D**, McFadden D, Newhouse JP. "Introduction" in D Goldman, D McFadden, JP Newhouse (eds.) *Journal of Health Economics*, 32(6), 2013.
110. Romley J, **Goldman D**, Eber M, et al. "Cost-Sharing and Initiation of Disease-Modifying Therapy for Multiple Sclerosis." *American Journal of Managed Care*, 18(8):460-464, 2012.
111. Darkow T, MacLean R, Joyce G, et al. "Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia." *American Journal of Managed Care*, 18(11 Suppl):s272-278, 2012.
112. Perloth D, Bhattacharya J, **Goldman D**, Garber A. "An Economic Analysis of Conservative Management versus Active Treatment for Men with Localized Prostate Cancer." *Journal of the National Cancer Institute Monographs*, 45:250-257, 2012.

113. Hagopian K, **Goldman D**. "The Health-Insurance Solution."  
*National Affairs*, Fall(13):95-111, 2012.
114. Thornton Snider J, et al. "Inhaled Corticosteroids and the Risk of Pneumonia in Medicare Patients with COPD."  
*Current Medical Research and Opinion*, 28(12):1959-1967, 2012.
115. Best J, Romley J, **Goldman D**, Conrad R, Peters A. "Expenditures for Medicaid Patients Treated with Exenatide Compared with Other Diabetes Management Regimens."  
*American Journal of Managed Care*, 18(8 Suppl): s191-202, 2012.
116. Barcellos S, **Goldman D**, Smith JP. "Undiagnosed Disease, Especially Diabetes, Casts Doubt on Some of Reported Health 'Advantage of Recent Mexican Immigrants.'"  
*Health Affairs*, 31(12):2727-2737, 2012.
117. Grabowski D, Lakdawalla D, **Goldman D**, et al. "The Large Social Value Resulting From Use of Statins Warrants Steps to Improve Adherence and Broaden Treatment."  
*Health Affairs*, 31(10):2276-2285, 2012.
118. Olshansky SJ, et al. "Differences in Life Expectancy due to Race and Educational Differences are Widening, and Many May Not Catch Up."  
*Health Affairs*, 31(8):1803-1813, 2012.
119. Romley J, **Goldman D**, Solomon M, McFadden D, Peters A. "Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population."  
*Diabetes Technology & Therapeutics*, 14(10):904-911, 2012.
120. Thornton Snider J, Romley J, Wong K, Zhang J, Eber M, **Goldman D**. "The Disability Burden of COPD."  
*COPD*, 9(5):513-521, 2012.
121. Michaud P, **Goldman D**, Lakdawalla D, Zheng Y, Gailey A. "The Value of Medical and Pharmaceutical Interventions for Reducing Obesity."  
*Journal of Health Economics*, 31(4):630-643, 2012.
122. **Goldman D**, Maestas N. "Medical Expenditure Risk and Household Portfolio Choice."  
*Journal of Applied Econometrics*, 28(4):527-550, 2012.
123. Seabury S, **Goldman D**, Maclean J, Penrod J, Lakdawalla D. "Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates."  
*Health Affairs*, 31(4):691-699, 2012.
124. Romley J, Sanchez Y, Penrod J, **Goldman D**. "Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs."  
*Health Affairs*, 31(4):683-690, 2012.
125. Philipson T, Eber M, Lakdawalla D, Corral M, Conti R, **Goldman D**. "An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer."  
*Health Affairs*, 31(4):667-675, 2012.
126. Karaca-Mandic P, Jena A, Joyce G, **Goldman D**. "Out-of-pocket medication costs and use of medications and health care services among children with asthma."  
*JAMA*, 307(12):1284-1291, 2012.
127. Romley JA, Hackbarth A, **Goldman D**. "The Impact of Air Quality on Hospital Spending."  
*Rand Health Q*, 2(3):6, 2012.
128. Huckfeldt P, Meeker D, Peters A, Guterman J, Diaz G, **Goldman D**. "Diabetes management for low-income patients in Los Angeles: two strategies improved disease control in the short term."  
*Health Affairs*, 31(1):168-176, 2012.

129. Jena A, **Goldman D**, Foster S, Califano J. "Prescription medication abuse and illegitimate internet-based pharmacies."  
*Annals of Internal Medicine*, 155(12):848-850, December, 2011.
130. Romley J, **Goldman D**. "How Costly is Hospital Quality? A Revealed-Preference Approach."  
*Journal of Industrial Economics*, 59(4):578-608, 2011.
131. Vogt W, et al. "Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics."  
*Health Affairs*, 30(12):2346-54, 2011.
132. **Goldman D**, Zissimopoulos J, Lu Y. "Medical Expenditure Measures in the Health and Retirement Study."  
*Forum for Health Economics and Policy*, 14(3):4, February 2011.
133. Joyce G, Carrera M, **Goldman D**, Sood N. "Physician Prescribing Behavior and its Impact on Patient-Level Outcomes."  
*American Journal of Managed Care*, 17(12):e462-71, 2011.
134. Hackbarth A, Romley J, **Goldman D**. "Racial and ethnic disparities in hospital care resulting from air pollution in excess of federal standards."  
*Social Science and Medicine*, 73(8):1163-1168, 2011.
135. **Goldman D**, Joyce G, Vogt W. "Part D Formulary and Benefit Design as a Risk-Steering Mechanism."  
*American Economic Review Papers and Proceedings*, 101(3):382-386, 2011.
136. Michaud, P, **Goldman D**. "Differences in Health between Americans and Western Europeans: Effects on Longevity and Public Finance."  
*Social Science and Medicine*, 73(2):254-263, July 2011.
137. Chernew M, **Goldman D**, Axeen S. "How Much Savings Can We Wring from Medicare?"  
*New England Journal of Medicine*, 365(14):e29(1)-e29(3), 2011.
138. Jena A, **Goldman D**. "Growing Internet Use May Help Explain The Rise In Prescription Drug Abuse In The United States."  
*Health Affairs*, 30(6):1192-1199, June 2011.
139. Baicker K, **Goldman D**. "Patient Cost-Sharing and Health Care Spending Growth."  
*Journal of Economic Perspectives*, 25(2):47-68, Spring 2011.
140. **Goldman D**, Smith JP. "The increasing value of education to health."  
*Social Science and Medicine*, 72(10):1728-1737, 2011.
141. **Goldman D**, Lakdawalla D, Philipson T. "Market exclusivity for drugs: the authors reply."  
*Health Affairs*, 30(4):799, April 2011.
142. Jena A, **Goldman D**, Joyce G. "Association Between the Birth of Twins and Parental Divorce."  
*Obstetrics & Gynecology*, 117(4):892-897, April 2011.
143. Romley J, Jena A, **Goldman D**. "Hospital spending and inpatient mortality: evidence from California: an observational study."  
*Annals of Internal Medicine*, 154(3):160-167, February 2011.
144. Meeker D, Joyce G, Malkin J, Teutsch S, Haddix A, **Goldman D**. "Coverage and Preventive Screening."  
*Health Services Research*, 46(1p1):173-184, February 2011.
145. **Goldman D**, Lakdawalla D, Malkin J, Romley J, Philipson T. "The Benefits of Giving Makers Of Conventional 'Small Molecule' Drugs Longer Exclusivity Over Clinical Trial Data."  
*Health Affairs*, 30(1):84-90, January 2011.
146. Perloth D, Garber A, **Goldman D**. "The Potential Impact of Comparative Effectiveness Research on U.S. Health Care Expenditures."  
*Demography*, 47(Supplement):S173-S190, 2010.

147. **Goldman D**, Vaiana M, Romley J. "The Emerging Importance of Patient Amenities in Hospital Care." *New England Journal of Medicine*, 363(23):2185-2187, December 2010.
148. **Goldman D**, Lakdawalla D, Philipson T, Yin W. "Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA." *Health Economics*, 19(10):1109-1116, October 2010.
149. Shang B, **Goldman D**. "Prescription Drug Coverage and Medicare Spending among U.S. Elderly." *The Geneva Papers on Risk and Insurance—Issues and Practice*, 35(4):539-567, October 2010.
150. Karaca-Mandic P, Joyce G, **Goldman D**, Laouri M. "Cost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis." *Health Services Research*, 45(5):1227-1250, October 2010.
151. Jena A, **Goldman D**, Kamdar A, Lakdawalla D, Lu Y. "Sexually transmitted diseases among users of erectile dysfunction drugs." *Annals of Internal Medicine*, 153(1):1-7, July 2010.
152. Michaud PC, **Goldman D**, Lakdawalla D, Zheng Y, Gailey A, Vaynman I. "The Fiscal Consequences of Trends in Population Health." *National Tax Journal*, 63(2):307-330, January 2010.
153. Antos J, Bertko J, Chernew M, Cutler D, Brantes F, **Goldman D**, et al. "Bending the Curve through Health Reform Implementation." *American Journal of Managed Care*, 16(11): 804-812, 2010.
154. Lakdawalla D, Sun E, Jena A, Reyes C, **Goldman D**, Philipson T. "An Economic Evaluation of the War on Cancer." *Journal of Health Economics*, 29(1):333-346, May 2010.
155. Philipson T, Seabury S, Lockwood L, **Goldman D**, Lakdawalla D. "Geographic Variation in Health Care: The Role of Private Markets." *Brookings Papers on Economic Activity*, 1:325-355, Spring 2010.
156. **Goldman D**, Lakdawalla D. "Can the ACA Improve Population Health?" *The Economists' Voice*, 7(5), Article 1, 2010.
157. **Goldman D**, Jena A, Lakdawalla D, Malin J, Malkin J, Sun E. "The Value of Specialty Oncology Drugs." *Health Services Research*, 45(1):115-132, 2010.
158. Sun E, Jena A, Lakdawalla D, Reyes C, Philipson T, **Goldman D**. "The Contributions of Improved Therapy and Early Detection to Cancer Survival Gains, 1988-2000." *Forum for Health Economics & Policy*, 13(2), 2010.
159. Antos J, Bertko J, Chernew M, Cutler D, **Goldman D**, McClellan M, McGlynn E, Pauly M, Schaeffer L, Shortell S. "Bending the Curve: Effective Steps to Address Long-Term Healthcare Spending Growth." *American Journal of Managed Care*, 15(10):676-680, 2009.
160. Olshansky J, **Goldman D**, Zheng Y, Rowe J. "Aging in America in the 21<sup>st</sup> Century: Demographic Forecasts from the MacArthur Research Network on an Aging Society." *Milbank Quarterly*, 87(4):842-862, 2009.
161. **Goldman D**, Zheng Y, Girosi F, et al. "The Benefits of Risk Factor Prevention in Americans Aged 51 and Older." *American Journal of Public Health*, 99(11):2096-2101, 2009.
162. Bhattacharya J, **Goldman D**, Sood N. "Market Evidence of Misperceived Mortality Risk." *Journal of Economic Behavior & Organization* 72(1):451-462, 2009.
163. Joyce G, **Goldman D**, Vogt W, Sun E, Jena A. "Medicare Part D After Two Years." *American Journal of Managed Care*, 15(8):31-39, 2009.

164. Solomon M, **Goldman D**, Joyce G, Escarce J. "Cost sharing and the initiation of drug therapy for the chronically ill."  
*Archives of Internal Medicine*, 169(8):740-748, 2009.
165. Arrow K, et al. "Toward a 21st century health care system: recommendations for health care reform."  
*Annals of Internal Medicine*, 150(7):493-495, 2009.
166. Sood N, de Vries H, Gutierrez I, Lakdawalla D, **Goldman D**. "The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries."  
*Health Affairs*, 28(1):w125–w137, 2009.
167. Lakdawalla D, **Goldman D**, Michaud P, et al., "U.S. Pharmaceutical Policy in a Global Marketplace."  
*Health Affairs*, 28(1):w138–w150, 2009.†
168. Ruelas V, Roybal G, Lu Y, **Goldman D**, Peters A. "Clinical and behavioral correlates of achieving and maintaining glycemic targets in an underserved population with type 2 diabetes."  
*Diabetes Care*, 32(1):54-56, 2009.
169. **Goldman D**, D McFadden. "Want to Monitor Medicare's New Drug Benefit Program? Start by Sending a Check for \$120,000."  
*The Economists' Voice*, 5(4), Article 1, 2008.
170. Joyce G, **Goldman D**, Karaca-Mandic P, Lawless G. "Impact of Specialty Drugs on Use of Other Medical Services."  
*American Journal of Managed Care*, 14(12): 821-828, 2008.
171. **Goldman D**, Joyce, G. "Medicare Part D: A Successful Start With Room for Improvement."  
*JAMA*, 299(16):1954-1955, 2008.
172. **Goldman D**, Jena A, Philipson T, Sun E. "Drug Licenses: A New Model for Pharmaceutical Pricing."  
*Health Affairs*, 27(1):122-129, 2008.
173. Kilgore M, **Goldman D**. "Drug Costs and Out-of-Pocket Spending in Clinical Trials."  
*Contemporary Clinical Trials*, 29:1-8, 2008.
174. Shang B, **Goldman D**. "Does Age or Life Expectancy Better Predict Health Care Expenditures?"  
*Health Economics*, 17:487–501, 2008.
175. **Goldman D**, Philipson T. "Integrated Insurance Design in the Presence of Multiple Medical Technologies."  
*American Economic Review*, 97(2): 427-432, 2007.
176. Garber A, **Goldman D**, Jena A. "The Promise of Health Care Cost-Containment."  
*Health Affairs*, 26(6):1545-1547, 2007.
177. **Goldman D**, Joyce G, Zheng Y. "Prescription Drug Cost Sharing: Association With Medication and Medical Utilization and Spending and Health."  
*JAMA*, 298(1):61-69, 2007.
178. Joyce, G, **Goldman D**, Karaca-Mandic P, Zheng Y. "Pharmacy Benefit Caps and the Chronically-III."  
*Health Affairs*, 26(5):1333-1344, 2007.
179. **Goldman D**, Joyce G, Karaca-Mandic P, Sood N. "Adverse Selection in Prescription Drug Plans."  
*Forum for Health Economics & Policy*, 9(1), 2007.
180. Lakdawalla D, Sood N, **Goldman D**. "HIV Breakthroughs and Risky Sexual Behavior."  
*Quarterly Journal of Economics*, 121(3):1063-1102, 2006.
181. **Goldman D**, Smith J, Sood N. "Immigrants and the Cost of Medical Care."  
*Health Affairs*, 25(6):1700-1711, 2006.

---

†Awarded the Eugene Garfield Economic Impact Prize.

182. **Goldman D**, Sood N. "Rising Medical Costs: Are We in Crisis?" *Health Affairs*, 25(5):w389, 2006.
183. **Goldman D**, Joyce G, Lawless G, Crown W, Willey V. "Benefit Design and Specialty Drug Use." *Health Affairs*, 25(5):1319-1331, 2006.
184. **Goldman D**, Joyce G, Karaca-Mandic P, Sood N. "Adverse Selection in Prescription Drug Plans." *Forum for Health Economics & Policy*, 9(1):Article 4, 2006.
185. **Goldman, D**, Joyce G, Karaca-Mandic P. "Varying Pharmacy Benefits With Clinical Status: The Case of Cholesterol-Lowering Therapy." *American Journal of Managed Care*, 12(1):21-28, 2006.
186. Bhattacharya J, **Goldman D**, McCaffrey D. "Estimating Probit Models with Endogenous Covariates." *Statistics in Medicine*, 25(3):389-413, 2006.
187. **Goldman D**, Cutler D, Shang B, Joyce G. "The Value of Elderly Disease Prevention." *Forum for Health Economics & Policy*, 9(2):1-29, 2006.
188. **Goldman D**, Smith J. "Socioeconomic Differences in the Adoption of New Medical Technologies." *American Economic Review Papers and Proceedings*, 95(2):234-237, 2005.
189. **Goldman D**, Smith J, Sood N. "Legal Status and Health Insurance among Immigrants." *Health Affairs*, 24(6):1640-1653, 2005.
190. **Goldman D**, Lakdawalla D. "A Theory of Health Disparities and Medical Technology." *Contributions to Economic Analysis & Policy*: 4(1):1-33, 2005.
191. **Goldman D**, et al. "Consequences of Health Trends and Medical Innovation for the Future Elderly." *Health Affairs*, Published online September 26, 2005.
192. Bhattacharya J, Shang B, Su C, **Goldman D**. "Technological Advance in Cancer and the Future of Medical Care Expenditures by the Elderly." *Health Affairs*, W5-R53, 2005.
193. Joyce G, Keeler E, Shang B, **Goldman D**. "The Lifetime Burden of Chronic Disease among the Elderly." *Health Affairs*, W5-R18, 2005.
194. Lakdawalla D, **Goldman D**, Shang B. "The Health and Cost Consequences of Obesity among the Future Elderly." *Health Affairs*, W5-R30, 2005.
195. Chernew M, **Goldman D**, Pan F, Shang B. "Disability and Health Care Expenditures among Medicare Beneficiaries." *Health Affairs*, W5-R42, 2005.
196. Shekelle P, Ortiz E, Newberry S, Rich M, Rhodes S, Brook R, **Goldman D**. "Identifying Potential Health Care Innovations for the Future Elderly." *Health Affairs*, W5-R67, 2005.
197. **Goldman D**, Sood N, Leibowitz A. "The Reallocation of Compensation in Response to Health Insurance Premium Increases." *Economics Letters*, 88(5):147-151, 2005.
198. **Goldman D**, Joyce G. "Moving Towards Better Formulary Management" [commentary]. *American Journal of Managed Care*, 11(1):13-15;2005
199. Joyce G, **Goldman D**, Leibowitz A, Alpert A, Bao Y. "A Socioeconomic Profile of Older Adults with HIV" *Journal of Health Care for the Poor and Underserved*, 16(1):19-28, 2005.
200. Bhattacharya J, **Goldman D**, Sood N. "Price Regulation in Secondary Insurance Markets." *Journal of Risk and Insurance*, 71(4):643-75, 2004.

201. **Goldman D**, Joyce G, Escarce J, Pace J, Solomon M, Laouri M, Landsman P, Teutsch S. "Pharmacy Benefits and The Use Of Drugs By The Chronically-Ill."  
*JAMA*, 291(19):2344-50, 2004.
202. Buntin M, Escarce J, **Goldman D**, Kan H, Laugesen M, Shekelle P. "Increased Medicare Expenditures for Physicians' Services: What are the Causes?"  
*Inquiry*, 41(1):83-94, 2004.
203. **Goldman D**, Bao Y. "Effective HIV Treatment and the Employment of HIV+ Adults."  
*Health Services Research*, 39(6):1687-1708, 2004.
204. Kan H, **Goldman D**, Keeler E, Danani N, Melnick G. "An Analysis of Unobserved Selection in an Inpatient Diagnostic Cost Group Model."  
*Health Services and Outcomes Research Methodology*, 4(2):71-91, 2004.
205. Lakdawalla D, Bhattacharya J, **Goldman D**. "Are the Young Becoming More Disabled?"  
*Health Affairs*, 23(1):168-176, 2004.
206. Malkin J, **Goldman D**, Joyce G. "The Changing Face of Pharmacy Benefit Design."  
*Health Affairs*, 23(1):194-199, 2004.
207. **Goldman D**, Leibowitz A, Robalino D. "Employee Responses to Health Insurance Premium Increases."  
*American Journal of Managed Care*, 10(1):41-47, 2004.
208. Bui A, Taira R, **Goldman D**, Dionisio J, Sayre J, Kangarloo H. "Effect of an Imaging-Based Streamlined Electronic Healthcare Process on Quality and Costs."  
*Academic Radiology* 11(1):13-20, 2004.
209. Bhattacharya J, Cutler D, **Goldman D**, et al. "Disability Forecasts and Future Medicare Costs."  
*Forum for Health Economics & Policy* 7:4, 2004.
210. Adams J, Schonlau M, Escarce J, Kilgore M, Schoenbaum M, **Goldman D**. "Sampling Patients Within and Across Health Care Providers: Multi-Stage Non-nested Samples in Health Services Research."  
*Health Services and Outcomes Research Methodology*, 4(3):151-167, 2003.
211. Bhattacharya J, **Goldman D**, Sood N. "The Link Between Public and Private Insurance and HIV Related Mortality."  
*Journal of Health Economics*, 22(6):1105-1122, 2003.
212. **Goldman D** and Zissimopoulos JM. "High out-of-Pocket Health Care Spending by the Elderly."  
*Health Affairs*, 22(3):194-202, 2003.
213. Bhattacharya J, **Goldman D**, Lakdawalla D. "Counterpoint: A Response to the Editorials by Manton and Williamson,"  
*Medical Care*, 41(1):28-31, 2003.
214. **Goldman D**. "Evaluating the Total Costs of Cancer" [commentary].  
*Oncology*, 17(1):119-120, 2003.
215. **Goldman D**, Leibowitz A, Joyce G, et al. "Insurance Status of HIV-infected Adults in the Post-HAART Era: Evidence from the United States."  
*Applied Health Economics and Health Policy*, 2(2):85-90, 2003.
216. **Goldman D**, Berry S, McCabe M, et al. "The Incremental Costs of NCI-Sponsored Clinical Trials."  
*JAMA*, 289(22):2970-2977, 2003.
217. **Goldman D**, Zissimopoulos JM. "The Distribution of Out-of-Pocket Health Care Expenses Among the Elderly."  
*Health Affairs*, 22(3):194-202, 2003.
218. Lewis J, Kilgore M, **Goldman D**, et al. "The Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials."  
*Journal of Clinical Oncology*, 21(7):1383-1389, 2003.

219. Lakdawalla D, **Goldman D**, et al. "Forecasting the Nursing Home Population"  
*Medical Care*, 41(1):8-20, 2003.
220. Joyce G, Escarce J, Solomon M, **Goldman D**. "Employer Drug Benefit Plans and Spending on Prescription Drugs."  
*JAMA*, 288(14):1733-1739, 2002.
221. **Goldman D**, Lakdawalla D. "A New Method for Determining Patient Payments for Outpatient Drugs."  
*American Journal of Managed Care* [commentary], 8(2):125-128, 2002.
222. **Goldman D**, Smith J. "Can Patient Self-Management Help Explain the SES Health Gradient?"  
*Proceedings of the National Academy of Sciences*, 99(16):10929-10934, 2002. ‡
223. **Goldman D**, Joyce G, Malkin J. "The Costs of a Medicare Prescription Drug Benefit."  
*Topics in Economic Analysis and Policy*, 2(1), 2002
224. **Goldman D**, Smith J. "Commentary: Methodological Biases in Estimating the Burden of Out-of-Pocket Expenses."  
*Health Services Research*, 35(6):1357-1370, 2001.
225. **Goldman D**, Bhattacharya J, McCaffrey D, Duan N, Leibowitz A, Joyce G, Morton S. "The Effect of Insurance on Mortality in an HIV+ Population in Care."  
*Journal of the American Statistical Association*, 96(455):883-894, 2001.
226. Schoenbaum M, Lewis J, Kilgore M, Weidmer B, Berry S, Escarce J, Wagle N, **Goldman D**. "Using Hospital Tumor Registries to Identify Research Subjects."  
*Health Services and Outcomes Research Methodology*, 2(1):67-76, 2001.
227. Bozzette S, Joyce G, McCaffrey D, Leibowitz A, Morton S, Berry S, Rastegar A, Timberlake D, Shapiro M, **Goldman D**. "Expenditures for the Care of HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy."  
*New England Journal of Medicine*, 344(11):817-23, 2001.
228. **Goldman D**. "Costs of Conducting Cancer Clinical Trials."  
*Managed Care and Cancer*, 3(2):14-18, 2001.
229. **Goldman D**, Bhattacharya J, Leibowitz A, et al. "The Impact of State Policy on the Costs of HIV Infection."  
*Medical Care Research and Review*, 58(1):31-59, 2001
230. **Goldman D**, Schoenbaum ML, Potosky A, et al. "Measuring the Incremental Cost of Clinical Cancer Research."  
*Journal of Clinical Oncology*, 19(1):105-110, 2001.
231. London A, Fleishman J, **Goldman D**, et al. "Use of Unpaid and Paid Home Care Services Among People with HIV Infection in the US."  
*AIDS Care*, 13(1):99-121, 2001.
232. Hamilton B, Ho V, **Goldman D**. "Queuing for Surgery: Is the U.S. or Canada Worse Off?"  
*The Review of Economics and Statistics*, 82(2):297-308, 2000.
233. Kangarloo H, Valdez J, Yao L, et al. "Improving the Quality of Care Through Routine Teleradiology Consultation."  
*Academic Radiology*, 7(3):149-155, 2000.
234. Zwanziger J, Kravitz R, Hosek S, Sloss E, Sullivan G, Kallich J, **Goldman D**. "Providing Managed Care Options for a Large Population: Evaluating the CHAMPUS Reform Initiative."  
*Military Medicine*, 165(5):403-410, 2000.

---

‡Awarded the NIHCM Excellence in Research Prize.

235. Andersen R, Bozzette S, Shapiro M, et al. "Access of Vulnerable Groups to Antiretroviral Therapy Among Persons in Care for HIV in the U.S." *Health Services Research*, 35(2):389-416, 2000.
236. **Goldman D**, Buchanan J, Keeler E. "Simulating the Impact of Medical Savings Accounts on Small Business." *Health Services Research*, 35(1):53-75, 2000.
237. Frankel M, Shapiro M, Duan N, et al. "National Probability Samples in Studies of Low-Prevalence Diseases. Part II: Designing and Implementing the HIV Cost and Services Utilization Study Sample." *Health Services Research*, 34(5):969-992, 1999.
238. Hernandez J, Coulter I, **Goldman D**, Freed J, Marcus M. "Managed Care in Dental Markets: Is the Experience of Medicine Relevant?" *Journal of Public Health in Dentistry*, 59(1):24-32, 1999.
239. Shapiro M, Morton S, McCaffrey D, et al. "Variations in the Care of HIV-Infected Adults in the United States." *JAMA*, 281(24):2305-2315, 1999.
240. Joyce G, **Goldman D**, Leibowitz A, et al. "Variation in Inpatient Resource Use in the Treatment of HIV—Do the Privately Insured Receive More Care?" *Medical Care*, 37(3):220-227, 1999.
241. **Goldman D**, Leibowitz A, Buchanan J. "Cost Containment and Adverse Selection in Medicaid HMOs." *Journal of the American Statistical Association*, 93(441):54-62, 1998.
242. Bozzette SA, Berry SH, Duan N, et al. "The Care of HIV-Infected Adults in the United States." *New England Journal of Medicine*, 339(26):1897-1904, 1998.
243. **Goldman D**, Leibowitz A, Buchanan J, Keesey J. "Redistributional Consequences of Community Rating." *Health Services Research*, 32(1):71-86, 1997.
244. Keeler E, Malkin J, **Goldman D**, Buchanan J. "Can Medical Savings Accounts for the Nonelderly Reduce Health Care Costs?" *JAMA*, 275(21):1666-1671, 1996.
245. **Goldman D**, Hosek S, Dixon L, Sloss E. "The Effects of Benefit Design and Managed Care on Health Care Costs." *Journal of Health Economics*, 14(4):401-418, 1995.
246. **Goldman D**. "Managed Care as a Public Cost Containment Mechanism." *RAND Journal of Economics*, 26(2):277-295, 1995.
247. Klerman J, **Goldman D**. "Job Loss Due to Health Insurance Mandates." *JAMA*, 272(7):552-556, 1994.
248. **Goldman D**, Clarke A, Garber A. "Creating the Costliest Orphan: The Orphan Drug Act in the Development of Ceredase." *International Journal of Technology Assessment in Health Care*, 8(4):583-597, 1992.

### Books

249. E Berndt, **D Goldman**, J Rowe (eds). *Economic Dimensions of Personalized and Precision Medicine*, Chicago and London: University of Chicago Press, 2019.

### Book Chapters and Reports

250. Franco A, **Goldman D**, Leive A, McFadden D. "A Cautionary Tale in Comparative Effectiveness Research: Pitfalls and Perils of Observational Data Analysis." in A Aizcorbe et al (eds.) *Measuring and Modeling Health Care Costs*, The University of Chicago; pp. 55-80, 2018.
251. Berndt E, **Goldman D**, Rowe J. "Introduction" in E Berndt, **D Goldman**, J Rowe (eds). *Economic Dimensions of Personalized and Precision Medicine*, Chicago and London: University of Chicago Press; pp. 1-8, 2019.

252. **Goldman D**, Seabury S, Brandon S. "Investing in Prevention to Address the Burden of Chronic Disease and Mental Health" in A Weil, R Dolan (eds.) *Reducing the Burden of Chronic Disease: A Report of the Aspen Health Strategy Group*, Washington DC: The Aspen Institute; pp. 55-76, 2019.
253. **Goldman D**, Joyce G. "Consumer Demand and Health Effects of Cost Sharing." *Handbook of Pharmaceutical Economics*, Oxford University Press; pp. 365-393, 2012.
254. **Goldman D**, Lakdawalla D. "Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products" in M Pauly, T McGuire, P Barros (eds.) *Handbook of Health Economics*, Volume 2. Waltham, MA: Elsevier; pp. 825-868, 2012.
255. Hurd M, Zheng Y, Girosi F, **Goldman D**. "The Effects of Tobacco Control Policy on the Social Security Trust Fund" in P Bearman, K Neckerman, L Wright (eds.) *After Tobacco: What Would Happen if Americans Stopped Smoking?* New York: Columbia University Press; pp. 290-321, 2011.
256. **Goldman D**, Lakdawalla D, Zheng Y. "Food Prices and the Dynamics of Body Weight" in M Grossman and N Mocan (eds.) *Economic Aspects of Obesity*. Chicago: University of Chicago Press; pp. 65-90, 2011.
257. Chernew M, **Goldman D**, Pan F, Shang B. "Disability and Spending Growth" in D Cutler and D Wise (eds.) *Health at Older Ages: The Causes and Consequences of Declining Disability Among the Elderly*. Chicago: University of Chicago Press, 2009.
258. Garber A and **Goldman D**. "The Changing Face of Health Care" in H Aaron and W Schwarz (eds.) *Coping with Methuselah: The Impact of Molecular Biology on Medicine and Society*. Washington, DC: Brookings Institution Press; pp. 105-125, 2004.
259. Bhattacharya J, Cutler D, **Goldman D**, Hurd M, Joyce G, Lakdawalla D, Panis C, Shang B. "Disability Forecasts and Future Medicare Costs" in D Cutler and A Garber (eds.) *Frontiers in Health Policy Research, Volume 7*. National Bureau of Economic Research, pp. 75-94, 2004.
260. **Goldman D**, Sood N, Leibowitz A. "Wage and Benefit Changes in Response to Rising Health Insurance Costs" in D Cutler and A Garber (eds.) *Frontiers in Health Policy Research, Volume 8*. National Bureau of Economic Research, 2005.
261. Alpert A, Garber A, **Goldman D**. "Societal Perspective: Comment" in A Futeran and A Zimran (eds.) *Gaucher Disease*. Boca Raton, Florida: CRC Press; pp. 489-498, 2006.
262. Buntin M, Escarce J, **Goldman D**, et al. Determinants of Increases in Medicare Expenditures for Physicians' Services. Technical Review 7. AHRQ Publication No. 04-0008, 2003.

### Editorials

263. **Goldman D**. "[Early Detection: A New Front in the War on Cancer.](#)" *Scientific American*, May 6, 2020.
264. Worsham C, Jena A, **Goldman D**. "[Where is Big Data when we need it most?](#)" *The Hill*, April 23, 2020.
265. Edlin A, **Goldman D**. "[How California's smog alert system could be adapted to fight the coronavirus.](#)" *Los Angeles Times*, April 19, 2020.
266. **Goldman D**. "[Obesity, second to smoking as the most preventable cause of US deaths, needs new approaches.](#)" *The Conversation*, January 27, 2020.
267. **Goldman D**. "[CBO estimate on Pelosi drug bill misses its long-term impact on health.](#)" *STAT*, October 16, 2019.
268. Chen A, **Goldman D**. "[Accounting for hope: using 'mean survival gain' to price new cancer drugs.](#)" *STAT*, October 14, 2019.

269. **Goldman D.** [“Why your employer-sponsored insurance may ultimately not be good for you.”](#)  
*The Conversation*, September 9, 2019.
270. **Goldman D.** [“Here's how we can control drug costs while spurring innovation.”](#)  
*The Hill*, June 14, 2019.
271. **Goldman D, Lakdawalla D.** [“Health Care’s Killer App: Life Insurance.”](#)  
*Wall Street Journal*, March 20, 2019.
272. Trish E, **Goldman D.** [“Ending drug rebates will increase Medicare Part D premiums. Most seniors will be insulated from it.”](#)  
*STAT*, February 21, 2019.
273. Chou J, Huber C, **Goldman D.** [“Double Jeopardy In Health— It’s Time For Employers To Care.”](#)  
*Health Affairs Blog*, December 10, 2018.
274. **Goldman D, Green R.** [“California needs public infrastructure, but not a bullet train.”](#)  
*Sacramento Bee*, October 11, 2018.
275. **Goldman D.** [“When we find a cure, price it like Netflix to ensure access.”](#)  
*The Hill*, August 13, 2018.
276. Mattke S, Lakdawalla D, **Goldman D.** [“The Long Road To Value-Based Payment: The Case Of Transcatheter Aortic Valve Replacement.”](#)  
*Health Affairs Blog*, July 26, 2018.
277. **Goldman D, Trish E.** [“Walmart and CVS have 15,000 combined stores. Why are both trying to buy health insurance companies?”](#)  
*Los Angeles Times*, April 10, 2018.
278. Jena A, **Goldman D.** [“Here's how we can increase the supply of organs and keep people off of the waiting list.”](#)  
*The Hill*, February 12, 2018.
279. **Goldman D and Lakdawalla D.** [“Opinion: This is what’s at stake if U.S. drug prices fall — and Europeans don’t pay more.”](#) *MarketWatch*, February 1, 2018.
280. Sood N, **Goldman D, Van Nuys K.** [“Follow the money to understand how drug profits flow.”](#)  
*STAT*, December 15, 2017.
281. Jena A, Barnett M, **Goldman D.** [“How Health Care Providers Can Help End the Overprescription of Opioids.”](#)  
*Harvard Business Review*, October 24, 2017.
282. **Goldman D.** [“Why Bernie Sanders’s plan for universal health care is only half right.”](#)  
*STAT*, September 12, 2017.
283. Agus D, **Goldman D.** [“Innovative Drugs Deserve Innovative Pricing.”](#)  
*Fortune*, August 31, 2017.
284. Howard P, **Goldman D.** [“This is how Congress could craft a bipartisan health-care bill.”](#)  
*MarketWatch*, July 30, 2017.
285. **Goldman D, Lakdawalla D.** [“Take Me Out to the Pill Game.”](#)  
*Wall Street Journal*, June 19, 2017.
286. Sood N, Shih T, Van Nuys K, **Goldman D.** [“Follow The Money: The Flow Of Funds In The Pharmaceutical Distribution System.”](#)  
*Health Affairs Blog*, June 13, 2017.
287. **Goldman D, Jena A.** [“Value-based drug pricing makes sense, but is difficult to pull off.”](#)  
*STAT*, June 8, 2017.
288. Hagopian K, **Goldman D.** [“How To Insure Everyone At A Reasonable Cost.”](#)  
*Forbes*, March 3, 2017.

289. Schaeffer L, **Goldman D.** "[California provides model to replace the Affordable Care Act.](#)" *Sacramento Bee*, February 14, 2017.
290. **Goldman D**, Lakdawalla D. "[Why academics consulting with industry on health care may be an idea whose time has come.](#)" *The Conversation*, December 21, 2016.
291. **Goldman D**, Lakdawalla D. "[Election Verdict: Pharma Needs A New Prescription.](#)" *STAT*, November 10, 2016.
292. **Goldman D**, Nussbaum S, Linthicum M. "[Rapid Biomedical Innovation Calls For Similar Innovation In Pricing And Value Measurement.](#)" *Health Affairs Blog*, September 15, 2016.
293. **Goldman, D.** "[To Prevent Another EpiPen Controversy, the Government Should Step In.](#)" *STAT*, August 26, 2016.
294. **Goldman D.** "[Hospital Care for Those Who Can Afford It Helps Care for Those Who Can't.](#)" *The New York Times*, August 22, 2016.
295. **Goldman D.** "[Commentary: To ensure access to generic drugs, take a lesson from vaccines.](#)" *Modern Healthcare*, June 29, 2016.
296. Chung A, MacEwan J, **Goldman D.** "[Does A 'One-Size-Fits-All' Formulary Policy Make Sense?](#)" *Health Affairs Blog*, June 2, 2016.
297. **Goldman, D.** "[Commentary: Drop Medicaid 'best price' drug rules in favor of value-based strategies.](#)" *Modern Healthcare*, November 18, 2015.
298. Romley J, **Goldman D**, Sood N. "[Hospital Productivity: The Authors Reply.](#)" *Health Affairs*, 34(6):1069, 2015.
299. **Goldman D**, Lakdawalla D. "[Moving Beyond Price-Per-Dose In The Pharmaceutical Industry.](#)" *Health Affairs Blog*, September 30, 2015.
300. Chandra A, **Goldman D.** "[Understanding Health Care's Short-Termism Problem.](#)" *Harvard Business Review*, Published online September 28, 2015.
301. **Goldman D**, Lakdawalla D, Newcomer L. "[It's Time For Value-Based Payment In Oncology.](#)" *Health Affairs Blog*, April 28, 2015.
302. **Goldman D** et al. "[Mortality Versus Survival In International Comparisons Of Cancer Care.](#)" *Health Affairs Blog*, March 20, 2015
303. Altman D, **Goldman D.** "[Medicare Spending Cuts and Hospital Productivity Gains.](#)" *The Wall Street Journal*, published online Feb 25, 2015.
304. **Goldman D**, Chandra A, Lakdawalla D. "[It's Easier to Measure the Cost of Health Care than Its Value.](#)" *Harvard Business Review*, Published online November 18, 2014.
305. Basu A, Jena A, **Goldman D**, Philipson T, Dubois R. "[Response to Epstein on 'Heterogeneity in Action.'](#)" *Health Economics*, January 21, 2014.
306. Hagopian K and **Goldman D.** "[How To Achieve Universal Health Coverage at Half the Cost.](#)" *Forbes Opinion*, January 10, 2014.
307. **Goldman D**, Leive A. "[Why 'Medicare-For-All' Is Not The Answer.](#)" *Health Affairs Blog*, May 14, 2013.
308. **Goldman D.** "[What Health Care Can Learn from Netflix.](#)" *LinkedIn*, May 27, 2013.
309. **Goldman D**, Chernew M, Jena AB. "[Health Insurance Exchanges May Be Too Small to Succeed.](#)" *New York Times*, November 23, 2012.

310. **Goldman D**, Schwartz S, Lakdawalla D, Philipson T, Jena A. "[Harnessing The Promise Of Comparative Effectiveness Research.](#)"  
*Health Affairs Blog*, September 12, 2012.
311. Seabury S, Lakdawalla D, **Goldman D**. "[Patients' Willingness To Pay: The Authors Reply.](#)"  
*Health Affairs*, 31(8): 1909, 2012.
312. Eber M, **Goldman D**, Lakdawalla D, Philipson T. "[When Epidemiology Goes Astray: Valuing Cancer Care in the United States and Europe.](#)"  
*Health Affairs Blog*, May 14, 2012.
313. Schaeffer L, **Goldman D**. "[Benefit Design Should Reflect Value.](#)"  
*Institute of Medicine Commentary*, January 27, 2012.
314. Chernew M, Lakdawalla D, **Goldman D**. "[Saving Medicare Dollars: Moving From The SGR To Bundled Payments.](#)"  
*Health Affairs Blog*, February 24, 2012.
315. Smith P, **Goldman D**. "[Can patient self-management explain the health gradient? Goldman and Smith \(2002\) revisited: A Response to Maitra.](#)"  
*Social Science & Medicine*, 70(1):813-815, 2010.
316. **Goldman D** and Shah V. "[Congress and Medicare.](#)"  
*Huffington Post*, May 31, 2011.
317. **Goldman D** and Edlin A. "[Can Immigrants Solve Our Health Care Problems?](#)"  
*New York Times*, January 19, 2010.
318. **Goldman D**. "[I am a Death Panelist. I am not the Problem.](#)"  
*New York Times*, December 9, 2009.
319. **Goldman D**. "[Fix the Healthcare System \(and Fight the Recession, Too\).](#)"  
*CNN.com*, August 21, 2009.
320. **Goldman D**. "[Improve Health, Not the Health Care System.](#)"  
*New York Times*, June 23, 2009.
321. **Goldman D**. "[Limiting Treatment to Those Who Need It.](#)"  
*KQED Healthy Ideas*, April 29, 2009.
322. **Goldman D**. "[Half Right.](#)"  
*Cato Unbound*, September 14, 2007.
323. Buntin M, Escarce J, **Goldman D**. "[Use of Physician Services for Medicare Beneficiaries.](#)"  
*New England Journal of Medicine*, 357(6):617-619, 2007.
324. **Goldman D**. "[Review of 'Shredding the Social Contract: The Privatization of Medicare' by John Geyman](#)"  
*New England Journal of Medicine*, 355(2): 217-218, 2006.
325. **Goldman D**, Malkin J. "[The HSA Mirage](#)"  
*United Press International*, February 20, 2006.
326. **Goldman D**. "[Pressure from rising health-care costs: How can consumers get relief?](#)"  
*Riverside Press Enterprise*, October 24, 2005.
327. **Goldman D** and Schuster M. "[Outside View: Health Costs of Katrina](#)"  
*United Press International*, October 10, 2005.
328. **Goldman D**. "[Review of 'Who Should Pay for Medicare?' by Daniel Shaviro](#)"  
*New England Journal of Medicine*, 351:405-407, 2004.
329. **Goldman D**, Joyce G. "[Take Two Aspirin and Call Congress.](#)"  
*Los Angeles Times*, December 11, 2002.

330. Wagle N, **Goldman D**, Kilgore M. "[Surveys identify barriers to participation in clinical trials.](#)" *Journal of the National Cancer Institute*, 93(3):238-239, 2001.
331. **Goldman D**, Joyce G. "[A Third—and Better—Way for Prescription Drug Coverage](#)" *Los Angeles Times*, November 5, 2000.

## DISSERTATION COMMITTEES

### **Laura Henkhaus\***

Title: Health care use, access, and economic welfare of adults with histories of childhood sexual abuse  
Year: 2019  
Position: <https://www.linkedin.com/in/laurahenkhaus/>

### **Eunhae Shin**

Title: Essays in Health Economics and Provider Behavior  
Year: 2019  
Position: <https://sites.google.com/view/eunhae-shin/home>

### **Wei-Han (Wendy) Cheng**

Title: The Value of PCSK9 inhibitors in the U.S. Healthcare System: Reducing the Burden of Cardiovascular Diseases and Filling the Gap of Low Adherence in Statins  
Year: 2018  
Position: <https://www.linkedin.com/in/wei-han-wendy-cheng-a8053834/>

### **Jakub Hlavka**

Title: Three Essays in Health Economics Towards Alternative Payment Models for High-Value, High-Cost Medical Treatments  
Year: 2018  
Position: <https://www.linkedin.com/in/jakubhlavka/>

### **Zhiwen (Richard) Xie**

Title: Three Essays on Health Economics  
Year: 2018  
Position: <https://www.linkedin.com/in/richard-zhiwen-xie-52598522/>

### **Amulya Yadav**

Title: Artificial Intelligence for Low-Resource Communities: Influence Maximization in an Uncertain World  
Year: 2018  
Position: <https://www.linkedin.com/in/amulyayadav/>

### **Wei Xie\***

Title: Panel Data Forecasting and Application to Epidemic Disease  
Year: 2016  
Position: <https://www.linkedin.com/in/wei-xie-961a2223/>

### **Sarah Axeen\***

Title: Essays in Opioid Use and Abuse  
Year: 2015  
Position: <https://www.linkedin.com/in/sarah-axeen-1553777/>

### **Lauren Scarpati**

Title: Essays in Health Economics: Evidence from Medicare

Year: 2015  
Position: <https://www.linkedin.com/in/lauren-scarpati-02641711/>

**Barbara Blaylock**

Title: Essays on the Use of Microsimulation for Health and Economic Policy Analysis  
Year: 2015  
Position: <https://www.linkedin.com/in/bablalock/>

**Margaret Blume-Kohout**

Title: Essays on Government Policy and Pharmaceutical Innovation  
Year: 2009  
Position: <https://www.linkedin.com/in/megbk/>

**Yang Lu**

Title: Three Essays on Health Behaviors and the Need for New Policy  
Year: 2009  
Position: <https://www.linkedin.com/in/yanglu/>

**Yuhui Zheng**

Title: Economic Determinants of Obesity Among Older Americans  
Year: 2008  
Position: <https://www.linkedin.com/in/yuhuizheng/>

**Serhii Ilchuk**

Title: Retirement Decisions of Women in Response to Spousal Health  
Year: 2005  
Position: <https://www.linkedin.com/in/serhii-ilchuk-261b013/>

**Baoping Shang\*\***

Title: Effects of Prescription Drug Coverage on Medicare Beneficiaries  
Year: 2005  
Position: <https://www.linkedin.com/in/baoping-shang-309b649/>

**Matthew Solomon\***

Title: The Effects of Pharmacy Benefits on Persons with Chronic Disease  
Year: 2005  
Position: <https://www.linkedin.com/in/matt-solomon-3234521/>

**Yuhua Bao**

Title: Estimating Effects of Pharmaceutical Innovations on Patients' Employment Outcomes  
Year: 2003  
Position: <https://aims.uw.edu/yuhua-bao-phd>

**Neeraj Sood**

Title: Economics of Viatical Settlements  
Year: 2003  
Position: <https://www.linkedin.com/in/neeraj-sood-444659/>

**Hongjun Kan\***

Title: Does the Medicare diagnostic cost group model adequately adjust for selection bias?  
Year: 2002  
Position: <https://www.linkedin.com/in/hong-kan-1580a4112/>

**Meredith Kilgore\***

Title: Cancer Clinical Trials: Effects of Trial Design on Participation and of Participation on Costs, with an Examination of Cost Analysis Methods and Data Sources  
 Year: 2002  
 Position: <https://www.linkedin.com/in/meredith-kilgore-6284336/>

**Moira Inkelas\***

Title: Incentives in a Specialty Carve-out  
 Year: 2000  
 Position: <https://www.linkedin.com/in/moira-inkelas-b7229415/>

**Leo Morales\***

Title: Assessing Patient Experience with Healthcare in Multicultural Settings  
 Year: 2000  
 Position: <https://www.linkedin.com/in/leo-morales-md-phd-facp-720b9914/>

\*Recipient of AHRQ dissertation grant

\*\*Recipient of Pardee RAND Graduate School Hagopian Award

**FUNDING****SELECTED GRANTS AND CONTRACTS (PI and co-PI activities only)**

2012-2023	Title:	Resource Center for Minority Aging Research <b>PI</b>
	Sponsor:	National Institutes of Health (P30AG043073)
	Amount:	\$4,229,511
2018-2022	Title:	Ensuring Access to Novel Alzheimer's and Dementia Treatments <b>Co-PI</b>
	Sponsor:	National Institutes of Health (R01AG062277)
	Amount:	\$1,472,383
2019-2020	Title:	Precision Medicine: Moving Theory into Practice <b>PI</b>
	Sponsor:	Agency for Healthcare Research and Quality (R13HS26821)
	Amount:	\$42,342
2017-2020	Title:	Establishing the Foundation for a National AD/ADRD Registry <b>Co-PI</b>
	Sponsor:	National Institutes of Health (R01AG055401)
	Amount:	\$175,000
2016-2020	Title:	The Long-Term Benefits of Interventions to Improve T2D Outcomes <b>Co-PI</b>
	Sponsor:	National Institutes of Health (R01DK107552)
	Amount:	\$2,005,653
2015-2019	Title:	One Year Day-and-Night Home Closed Loop in Young People with T1D <b>Co-PI</b>
	Sponsor:	National Institutes of Health (UC4DK108520)
	Amount:	\$6,300,518
2004-2019	Title:	Roybal Center for Health Policy Simulation <b>PI</b>
	Sponsor:	National Institute on Aging (P30AG024968)
	Amount:	\$3,017,623
2013-2019	Title:	Transforming Research and Clinical Knowledge in Traumatic Brain Injury II <b>PI</b>
	Sponsor:	NINDS (U01)
	Amount:	\$770,663
2014-2016	Title:	Technological Innovation in Health Care and the Long-Term Outlook
	Sponsor:	National Institutes of Health
	Amount:	\$242,971

2011-2016	Title: An Economic and Behavioral Evaluation of Medicare Part D <b>PI</b> Sponsor: National Institute on Aging (P01AG033559) Amount: \$1,931,757
2012-2015	Title: MacArthur Foundation Research Network on Aging Society <b>PI</b> Sponsor: MacArthur Foundation Amount: \$500,750
2011-2015	Title: Trajectories and Palliation Study (TAPS) <b>PI</b> Sponsor: RAND Corporation Amount: \$241,458
2010-2013	Title: The Science of Medicare Reform <b>CO-PI</b> Sponsor: National Institutes of Health (RC4AG039036) Amount: \$5,500,668
2008-2013	Title: Improving Pharmacy Benefit Design <b>PI</b> Sponsor: National Institute on Aging (R01AG029514) Amount: \$825,770
2010-2012	Title: Aging Society Benefits and Cost of Interventions <b>PI</b> Sponsor: MacArthur Foundation Amount: \$431,623
2009-2012	Title: Economics of Treating Viral STIs <b>PI</b> Sponsor: National Institutes of Health (5R01HD054877) Amount: \$498,726
2009-2012	Title: Private Insurance and Prescription Outcomes for Children <b>PI</b> Sponsor: National Institutes of Health (5R03D058203) Amount: \$118,906
2009-2012	Title: Quality of Life and Productivity <b>PI</b> Sponsor: InHealth Amount: \$879,808
2007-2012	Title: Robust Integration Modeling of Health, Wealth and Disability Sponsor: National Institute on Aging (1R01AG030824) Amount: \$2,929,374
2006-2012	Title: Obesity Among Older Americans <b>PI</b> Sponsor: National Institute on Aging (R01AG025743) Amount: \$234,072
2009-2011	Title: A Patient Centered Diabetes Registry <b>PI</b> Sponsor: Institute for Health Technology Studies Amount: \$879,807
2003-2011	Title: Education, Self-Management, and Adherence Sponsor: National Institute on Aging (5R01AG023363) Amount: \$1,692,176
2000-2008	Title: Mini-Medical School for Social Scientists <b>PI</b> Sponsor: National Institute on Aging (5R13AG018327) Amount: \$245,850

Goldman\27

2006-2007	Title: Understanding How Cost-Sharing Affects Use of Specialty Drugs Sponsor: Genentech Amount: \$300,000
2003-2007	Title: An Investigation of the Viatical Settlements Market <b>PI</b> Sponsor: National Institute on Aging (5R01AG022351) Amount: \$948,999
2005-2007	Title: Public Policy and Pharmaceutical Innovation Around the World Sponsor: Pfizer Incorporated Amount: \$1,900,000
2005-2005	Title: Snapshot of Medicare and Medicare Consumers in California Sponsor: California Healthcare Foundation Amount: \$95,150
2005	Title: Economic Consequences of Medical Research Sponsor: NIH (Office of the Director) Amount: \$99,903
2004-2005	Title: Costs of Treating Chronic Disease in the United States and Germany Sponsor: Techniker Krankenkasse Amount: \$250,000
2004-2005	Title: The Impact of Cost-Sharing on the Severely Ill Sponsor: Amgen, Inc. Amount: \$324,665
2003-2005	Title: Immigrants' Low Rates Of Health Insurance Sponsor: University of Michigan Amount: \$104,351
2001-2005	Title: State and Federal Policy and Outcomes for HIV+ Adults <b>PI</b> Sponsor: Agency for Healthcare Research and Quality (1R01HS010846) Amount: \$741,722
2003	Title: The Consequences of Premium Regulation in California Sponsor: California Health Care Foundation Amount: \$95,000
2002-2003	Title: Responsiveness of Drug Expenditures to Drug Benefit Changes Sponsor: Merck & Co, Inc. Amount: \$75,000
2000-2003	Title: Impact of Drug Benefit Design on Health Care Costs Sponsor: California Healthcare Foundation Amount: \$92,134
2000-2001	Title: The Impact of Prescription Drug Benefits Sponsor: California Healthcare Foundation Amount: \$698,917

Goldman\28

1999-2003	Title:	Health Status and Medical Treatment of the Future Elderly: Implications for Medicare Program Expenditures
	Sponsor:	Center for Medicare and Medicaid Services
	Amount:	\$1,260,259
1999-2002	Title:	Cost of Cancer Treatment Study
	Sponsor:	NIH, NCI, and NSF
	Amount:	\$3,118,310
1999-2002	Title:	Insurance Choices in the Medicare Population
	Sponsor:	National Institute on Aging
	Amount:	\$648,406
1998-2002	Title:	Evaluation of the Medicare/DoD Subvention Demonstration
	Sponsor:	Health Care Financing Administration
	Amount:	\$1,411,439
1998	Title:	Feasibility Study to Measure the Cost of Cancer Trials
	Sponsor:	National Cancer Institute and National Science Foundation
	Amount:	\$400,000
1993-1994	Title:	HMO Cost Performance: A Simultaneous Equations Approach
	Sponsor:	Agency for Health Care Policy and Research
	Amount:	\$22,000

#### **ADDITIONAL AFFILIATIONS AND EXTERNAL ACTIVITIES**

Over the course of his career, Dr. Goldman has received research support, speaker fees, travel assistance, or consulting income from the following sources: Abbott, AbbVie, ACADIA Pharmaceuticals, Alkermes, Allergan, Alphabet, American Dental Association, American Medical Association, Amgen, Aspen Institute, Avanir, BIO, Biogen, Blue Cross Blue Shield of Massachusetts, Blue Cross Blue Shield of Arizona, Bristol Myers-Squibb, Celgene, California Hospital Association, Cambia Health Solutions, Cedars-Sinai Medical Center, Centers for Medicare & Medicaid Services, Claremont College, Commonwealth Fund, Columbia University, Congressional Budget Office, Dignity Health, Edwards Lifesciences, Eli Lilly, EMD Sorono, FAIR Health, Gemvax, Genentech, General Electric, Gilead Sciences, GRAIL, GSK, Intuitive Surgical, Johnson & Johnson, Kaiser Family Foundation, LA Biomed, Lockheed Martin, MacArthur Foundation, Merck, National Cancer Institute, National Institute on Aging, National Institutes of Health, National Pharmaceutical Council, National Science Foundation, National Railway Labor Conference, Novartis, Novo Nordisk, Otonomy, Otsuka Pharmaceuticals, Pfizer, PhRMA, Precision Health Economics, Providence St Joseph Health, RAND Corporation, Roche, Sanofi, Stanford University, Takeda, University of Arizona, University of California, University of Chicago, Walgreen Boots Alliance, West Coast Healthcare, and Western University College of Pharmacy. He owns equity (<1%) in the parent company of Precision Health Economics.